Zanubrutinib-based Maintenance Therapy of Newly Diagnosed DLBCL With Initial Remission

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2024

Primary Completion Date

November 30, 2026

Study Completion Date

December 31, 2027

Conditions

Diffuse Large B Cell Lymphoma

Interventions

DRUG

Zanubrutinib

160 mg bid, po, day 1-21, a maximum of 2 years.

DRUG

Lenalidomide

25 mg qd, po, day 1-10, a maximum of 2 years.

All Listed Sponsors

lead

Ruijin Hospital

OTHER

NCT06669143 - Zanubrutinib-based Maintenance Therapy of Newly Diagnosed DLBCL With Initial Remission | Biotech Hunter | Biotech Hunter